Suppr超能文献

磷脂/两性霉素B比例及磷脂类型对脂质体两性霉素B制剂体外肾细胞毒性和杀菌活性的影响。

Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.

作者信息

Joly V, Bolard J, Saint-Julien L, Carbon C, Yeni P

机构信息

Laboratoire d'Etude des Traitements Antiinfectieux, Faculté Xavier Bichat, Université Paris 7, France.

出版信息

Antimicrob Agents Chemother. 1992 Feb;36(2):262-6. doi: 10.1128/AAC.36.2.262.

Abstract

We studied the influence of the lipid/amphotericin B (AMB) ratio and the phospholipid type on the in vitro renal cell toxicity and antifungal efficacy of lipid-associated AMB (L-AMB). L-AMB was prepared at one of two different lipid/AMB ratios (1 and 40) by incubating AMB with empty small unilamellar vesicles, made from one of three different phospholipids: dipalmitoyl-, dimirystoyl-, and distearoylphosphatidylcholine (DPPC, DMPC, and DSPC, respectively). Renal cell toxicity, investigated through an assessment of the Na-dependent uptake of phosphate by proximal tubular cells, and fungicidal effect against Candida albicans were studied after 1 h of treatment at 37 degrees C. The amount of unbound AMB present in each L-AMB formulation was studied by use of circular dichroism. At a lipid/AMB ratio of 40, the three lipidic formulations were not toxic for renal cells but were less effective against C. albicans than AMB; however, DSPC-AMB, which contained 50% unbound AMB, was more effective against C. albicans than DPCC-AMB or DMPC-AMB, containing 0 and 13% unbound AMB, respectively. At a lipid/AMB ratio of 1, the antifungal effects of L-AMB and AMB were similar, whatever the phospholipid used, but only DMPC-AMB remained highly protective against AMB renal cell toxicity, despite the presence of the same amount of unbound AMB (50%) in DMPC-AMB and DPPC-AMB. We conclude that the in vitro activities and renal cell toxicities of different L-AMB formulations are influenced by the phospholipid type and the lipid/AMB ratio. The optimal ratio depends on the phospholipid itself. At a lipid/AMB ratio of 40, the antifungal activity depends mainly on the amount of unbound AMB in the formulation. At a lipid/AMB ratio of 1, the renal cell toxicity also depends on the fluidity of the phospholipid.

摘要

我们研究了脂质/两性霉素B(AMB)比例和磷脂类型对脂质体两性霉素B(L-AMB)体外肾细胞毒性和抗真菌疗效的影响。通过将AMB与由三种不同磷脂之一制成的空小单层囊泡孵育,以两种不同的脂质/AMB比例(1和40)之一制备L-AMB,这三种磷脂分别为二棕榈酰磷脂酰胆碱、二肉豆蔻酰磷脂酰胆碱和二硬脂酰磷脂酰胆碱(分别为DPPC、DMPC和DSPC)。在37℃处理1小时后,通过评估近端肾小管细胞对磷酸盐的钠依赖性摄取来研究肾细胞毒性,并研究对白色念珠菌的杀菌作用。使用圆二色性研究每种L-AMB制剂中未结合AMB的量。在脂质/AMB比例为40时,三种脂质制剂对肾细胞无毒,但对白色念珠菌的效力低于AMB;然而,含有50%未结合AMB的DSPC-AMB对白色念珠菌的效力高于分别含有0%和13%未结合AMB的DPCC-AMB或DMPC-AMB。在脂质/AMB比例为1时,无论使用何种磷脂,L-AMB和AMB的抗真菌效果相似,但只有DMPC-AMB对AMB肾细胞毒性仍具有高度保护作用,尽管DMPC-AMB和DPPC-AMB中存在相同量的未结合AMB(50%)。我们得出结论,不同L-AMB制剂的体外活性和肾细胞毒性受磷脂类型和脂质/AMB比例的影响。最佳比例取决于磷脂本身。在脂质/AMB比例为40时,抗真菌活性主要取决于制剂中未结合AMB的量。在脂质/AMB比例为1时,肾细胞毒性也取决于磷脂的流动性。

相似文献

5
Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
Int J Nanomedicine. 2014 Nov 24;9:5403-13. doi: 10.2147/IJN.S71623. eCollection 2014.
7
Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments.
J Antimicrob Chemother. 2005 May;55(5):727-34. doi: 10.1093/jac/dki064. Epub 2005 Mar 10.

引用本文的文献

1
Combination treatment of invasive fungal infections.
Clin Microbiol Rev. 2005 Jan;18(1):163-94. doi: 10.1128/CMR.18.1.163-194.2005.
2
Carrier effects on biological activity of amphotericin B.
Clin Microbiol Rev. 1996 Oct;9(4):512-31. doi: 10.1128/CMR.9.4.512.
3
Evidence for the formation of amphotericin B-phospholipid complexes in Langmuir monolayers.
Pharm Res. 1996 Jul;13(7):1008-14. doi: 10.1023/a:1016046321726.
6
In vitro models for studying toxicity of antifungal agents.
Antimicrob Agents Chemother. 1992 Sep;36(9):1799-804. doi: 10.1128/AAC.36.9.1799.
7
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
Clin Pharmacokinet. 1992 Oct;23(4):279-91. doi: 10.2165/00003088-199223040-00004.

本文引用的文献

1
Amphotericin B in liposomes: a novel therapy for histoplasmosis.
Am Rev Respir Dis. 1982 May;125(5):610-1. doi: 10.1164/arrd.1982.125.5.610.
4
Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice.
Antimicrob Agents Chemother. 1984 Aug;26(2):170-3. doi: 10.1128/AAC.26.2.170.
5
In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.
Antimicrob Agents Chemother. 1984 Mar;25(3):387-9. doi: 10.1128/AAC.25.3.387.
6
Antifungal agents useful in therapy of systemic fungal infections.
Annu Rev Pharmacol Toxicol. 1983;23:303-30. doi: 10.1146/annurev.pa.23.040183.001511.
7
Empiric amphotericin B therapy in patients with acute leukemia.
Rev Infect Dis. 1985 Sep-Oct;7(5):619-24. doi: 10.1093/clinids/7.5.619.
9
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
J Clin Oncol. 1987 Feb;5(2):310-7. doi: 10.1200/JCO.1987.5.2.310.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验